NASDAQ, GTXI - GTX Inc
GTx, Inc., a Delaware corporation incorporated on September 24, 1997, is a
biopharmaceutical company dedicated to the discovery, development and
commercialization of small molecules that selectively target hormone pathways to
treat cancer, osteoporosis and bone loss, muscle wasting and other serious
medical conditions. We are developing ACAPODENE? (toremifene citrate), a
selective estrogen receptor modulator, or SERM, in two separate clinical
programs in men: first, a pivotal Phase III clinical trial for the treatment of
multiple serious side effects of androgen deprivation therapy, or ADT, for
advanced prostate cancer, and second, a pivotal Phase III clinical trial for the
prevention of prostate cancer in high risk men with precancerous prostate
lesions called high grade prostatic intraepithelial neoplasia, or high grade
PIN. ...
Read SEC Filing on NASDAQ.com »